Loading…

Depression in dialysis patients

Depression is the most common psychiatric illness in patients with end‐stage renal disease (ESRD). The reported prevalence of depression in dialysis population varied from 22.8% (interview‐based diagnosis) to 39.3% (self‐ or clinician‐administered rating scales). Such differences were attributed to...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology (Carlton, Vic.) Vic.), 2016-08, Vol.21 (8), p.639-646
Main Authors: Ma, Terry King‐Wing, Li, Philip Kam‐Tao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5252-351e002c6c56b908cf1809cde5888ec85feb129bb148c455de98376e31b109cb3
cites cdi_FETCH-LOGICAL-c5252-351e002c6c56b908cf1809cde5888ec85feb129bb148c455de98376e31b109cb3
container_end_page 646
container_issue 8
container_start_page 639
container_title Nephrology (Carlton, Vic.)
container_volume 21
creator Ma, Terry King‐Wing
Li, Philip Kam‐Tao
description Depression is the most common psychiatric illness in patients with end‐stage renal disease (ESRD). The reported prevalence of depression in dialysis population varied from 22.8% (interview‐based diagnosis) to 39.3% (self‐ or clinician‐administered rating scales). Such differences were attributed to the overlapping symptoms of uraemia and depression. Systemic review and meta‐analysis of observational studies showed that depression was a significant predictor of mortality in dialysis population. The optimal screening tool for depression in dialysis patients remains uncertain. The Beck Depression Inventory (BDI), Patient Health Questionnaire (PHQ) and Center for Epidemiologic Studies Depression Scale (CESD) have been validated for screening purposes. Patients who scored ≥14 using BDI should be referred to a psychiatrist for early evaluation. Structured Clinical Interview for DSM disorders (SCID) remains the gold standard for diagnosis. Non‐pharmacological treatment options include cognitive behavioural therapy and exercise training programs. Although frequent haemodialysis may have beneficial effects on patients' physical and mental well‐being, it cannot and should not be viewed as a treatment of depression. Selective serotonin reuptake inhibitors (SSRIs) are generally effective and safe in ESRD patients, but most studies were small, non‐randomized and uncontrolled. The European Renal Best Practice (ERBP) guideline suggests a trial of SSRI for 8 to 12 weeks in dialysis patients who have moderate–major depression. The treatment effect should be re‐evaluated after 12 weeks to avoid prolonging ineffective medication. This review will discuss the current understanding in the diagnosis and management of depression in dialysis patients. Summary at a Glance This review examines some current features of the diagnosis and management of depression in dialysis patients. The overlapping symptoms of kidney failure managed with dialysis and depression and their interpretation are highlighted. The evidence and rationale for treatment are discussed.
doi_str_mv 10.1111/nep.12742
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808639964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1806076418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5252-351e002c6c56b908cf1809cde5888ec85feb129bb148c455de98376e31b109cb3</originalsourceid><addsrcrecordid>eNqN0MtKw0AUBuBBFC_VhS-gBTe6iJ37ZSmt91K7UApuhmRyCqNpEjMt2rd3NK0LQXA2Zxbf-eH8CB0SfE7i65VQnxOqON1Au4RznBBl1Gb8M4oTwYTeQXshvGBMFJVkG-1QqSXGiu2i4wHUDYTgq7Lry27u02IZfOjW6dxDOQ_7aGuaFgEOVrODnq4uH_s3yfDh-rZ_MUycoIImTBDAmDrphMwM1m5KNDYuB6G1BqfFFDJCTZYRrh0XIgejmZLASEaiy1gHnba5dVO9LSDM7cwHB0WRllAtgo1xWjJjJP8PlVhJTnSkJ7_oS7VoyniIpZgbJY3UJKqzVrmmCqGBqa0bP0ubpSXYfhVsY8H2u-Boj1aJi2wG-Y9cNxpBrwXvvoDl30l2dDleRybthg9z-PjZSJtXKxVTwk5G13bAx3d9NXm29-wTpLKQUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2049769681</pqid></control><display><type>article</type><title>Depression in dialysis patients</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Ma, Terry King‐Wing ; Li, Philip Kam‐Tao</creator><creatorcontrib>Ma, Terry King‐Wing ; Li, Philip Kam‐Tao</creatorcontrib><description>Depression is the most common psychiatric illness in patients with end‐stage renal disease (ESRD). The reported prevalence of depression in dialysis population varied from 22.8% (interview‐based diagnosis) to 39.3% (self‐ or clinician‐administered rating scales). Such differences were attributed to the overlapping symptoms of uraemia and depression. Systemic review and meta‐analysis of observational studies showed that depression was a significant predictor of mortality in dialysis population. The optimal screening tool for depression in dialysis patients remains uncertain. The Beck Depression Inventory (BDI), Patient Health Questionnaire (PHQ) and Center for Epidemiologic Studies Depression Scale (CESD) have been validated for screening purposes. Patients who scored ≥14 using BDI should be referred to a psychiatrist for early evaluation. Structured Clinical Interview for DSM disorders (SCID) remains the gold standard for diagnosis. Non‐pharmacological treatment options include cognitive behavioural therapy and exercise training programs. Although frequent haemodialysis may have beneficial effects on patients' physical and mental well‐being, it cannot and should not be viewed as a treatment of depression. Selective serotonin reuptake inhibitors (SSRIs) are generally effective and safe in ESRD patients, but most studies were small, non‐randomized and uncontrolled. The European Renal Best Practice (ERBP) guideline suggests a trial of SSRI for 8 to 12 weeks in dialysis patients who have moderate–major depression. The treatment effect should be re‐evaluated after 12 weeks to avoid prolonging ineffective medication. This review will discuss the current understanding in the diagnosis and management of depression in dialysis patients. Summary at a Glance This review examines some current features of the diagnosis and management of depression in dialysis patients. The overlapping symptoms of kidney failure managed with dialysis and depression and their interpretation are highlighted. The evidence and rationale for treatment are discussed.</description><identifier>ISSN: 1320-5358</identifier><identifier>EISSN: 1440-1797</identifier><identifier>DOI: 10.1111/nep.12742</identifier><identifier>PMID: 26860073</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Antidepressive Agents - therapeutic use ; Cognitive ability ; Cognitive Therapy ; depression ; Depression - diagnosis ; Depression - epidemiology ; Depression - psychology ; Depression - therapy ; Diagnosis ; Dialysis ; Epidemiology ; Hemodialysis ; Humans ; Kidney Failure, Chronic - diagnosis ; Kidney Failure, Chronic - epidemiology ; Kidney Failure, Chronic - psychology ; Kidney Failure, Chronic - therapy ; Medicare ; Mental depression ; Patients ; Physical training ; Predictive Value of Tests ; Psychiatric Status Rating Scales ; Renal Dialysis - adverse effects ; Risk Factors ; Serotonin uptake inhibitors ; Severity of Illness Index ; Surveys and Questionnaires ; Treatment Outcome</subject><ispartof>Nephrology (Carlton, Vic.), 2016-08, Vol.21 (8), p.639-646</ispartof><rights>2016 Asian Pacific Society of Nephrology</rights><rights>2016 Asian Pacific Society of Nephrology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5252-351e002c6c56b908cf1809cde5888ec85feb129bb148c455de98376e31b109cb3</citedby><cites>FETCH-LOGICAL-c5252-351e002c6c56b908cf1809cde5888ec85feb129bb148c455de98376e31b109cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26860073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Terry King‐Wing</creatorcontrib><creatorcontrib>Li, Philip Kam‐Tao</creatorcontrib><title>Depression in dialysis patients</title><title>Nephrology (Carlton, Vic.)</title><addtitle>Nephrology</addtitle><description>Depression is the most common psychiatric illness in patients with end‐stage renal disease (ESRD). The reported prevalence of depression in dialysis population varied from 22.8% (interview‐based diagnosis) to 39.3% (self‐ or clinician‐administered rating scales). Such differences were attributed to the overlapping symptoms of uraemia and depression. Systemic review and meta‐analysis of observational studies showed that depression was a significant predictor of mortality in dialysis population. The optimal screening tool for depression in dialysis patients remains uncertain. The Beck Depression Inventory (BDI), Patient Health Questionnaire (PHQ) and Center for Epidemiologic Studies Depression Scale (CESD) have been validated for screening purposes. Patients who scored ≥14 using BDI should be referred to a psychiatrist for early evaluation. Structured Clinical Interview for DSM disorders (SCID) remains the gold standard for diagnosis. Non‐pharmacological treatment options include cognitive behavioural therapy and exercise training programs. Although frequent haemodialysis may have beneficial effects on patients' physical and mental well‐being, it cannot and should not be viewed as a treatment of depression. Selective serotonin reuptake inhibitors (SSRIs) are generally effective and safe in ESRD patients, but most studies were small, non‐randomized and uncontrolled. The European Renal Best Practice (ERBP) guideline suggests a trial of SSRI for 8 to 12 weeks in dialysis patients who have moderate–major depression. The treatment effect should be re‐evaluated after 12 weeks to avoid prolonging ineffective medication. This review will discuss the current understanding in the diagnosis and management of depression in dialysis patients. Summary at a Glance This review examines some current features of the diagnosis and management of depression in dialysis patients. The overlapping symptoms of kidney failure managed with dialysis and depression and their interpretation are highlighted. The evidence and rationale for treatment are discussed.</description><subject>Antidepressive Agents - therapeutic use</subject><subject>Cognitive ability</subject><subject>Cognitive Therapy</subject><subject>depression</subject><subject>Depression - diagnosis</subject><subject>Depression - epidemiology</subject><subject>Depression - psychology</subject><subject>Depression - therapy</subject><subject>Diagnosis</subject><subject>Dialysis</subject><subject>Epidemiology</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - diagnosis</subject><subject>Kidney Failure, Chronic - epidemiology</subject><subject>Kidney Failure, Chronic - psychology</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Medicare</subject><subject>Mental depression</subject><subject>Patients</subject><subject>Physical training</subject><subject>Predictive Value of Tests</subject><subject>Psychiatric Status Rating Scales</subject><subject>Renal Dialysis - adverse effects</subject><subject>Risk Factors</subject><subject>Serotonin uptake inhibitors</subject><subject>Severity of Illness Index</subject><subject>Surveys and Questionnaires</subject><subject>Treatment Outcome</subject><issn>1320-5358</issn><issn>1440-1797</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqN0MtKw0AUBuBBFC_VhS-gBTe6iJ37ZSmt91K7UApuhmRyCqNpEjMt2rd3NK0LQXA2Zxbf-eH8CB0SfE7i65VQnxOqON1Au4RznBBl1Gb8M4oTwYTeQXshvGBMFJVkG-1QqSXGiu2i4wHUDYTgq7Lry27u02IZfOjW6dxDOQ_7aGuaFgEOVrODnq4uH_s3yfDh-rZ_MUycoIImTBDAmDrphMwM1m5KNDYuB6G1BqfFFDJCTZYRrh0XIgejmZLASEaiy1gHnba5dVO9LSDM7cwHB0WRllAtgo1xWjJjJP8PlVhJTnSkJ7_oS7VoyniIpZgbJY3UJKqzVrmmCqGBqa0bP0ubpSXYfhVsY8H2u-Boj1aJi2wG-Y9cNxpBrwXvvoDl30l2dDleRybthg9z-PjZSJtXKxVTwk5G13bAx3d9NXm29-wTpLKQUw</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Ma, Terry King‐Wing</creator><creator>Li, Philip Kam‐Tao</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>201608</creationdate><title>Depression in dialysis patients</title><author>Ma, Terry King‐Wing ; Li, Philip Kam‐Tao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5252-351e002c6c56b908cf1809cde5888ec85feb129bb148c455de98376e31b109cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antidepressive Agents - therapeutic use</topic><topic>Cognitive ability</topic><topic>Cognitive Therapy</topic><topic>depression</topic><topic>Depression - diagnosis</topic><topic>Depression - epidemiology</topic><topic>Depression - psychology</topic><topic>Depression - therapy</topic><topic>Diagnosis</topic><topic>Dialysis</topic><topic>Epidemiology</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - diagnosis</topic><topic>Kidney Failure, Chronic - epidemiology</topic><topic>Kidney Failure, Chronic - psychology</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Medicare</topic><topic>Mental depression</topic><topic>Patients</topic><topic>Physical training</topic><topic>Predictive Value of Tests</topic><topic>Psychiatric Status Rating Scales</topic><topic>Renal Dialysis - adverse effects</topic><topic>Risk Factors</topic><topic>Serotonin uptake inhibitors</topic><topic>Severity of Illness Index</topic><topic>Surveys and Questionnaires</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Terry King‐Wing</creatorcontrib><creatorcontrib>Li, Philip Kam‐Tao</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology (Carlton, Vic.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Terry King‐Wing</au><au>Li, Philip Kam‐Tao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Depression in dialysis patients</atitle><jtitle>Nephrology (Carlton, Vic.)</jtitle><addtitle>Nephrology</addtitle><date>2016-08</date><risdate>2016</risdate><volume>21</volume><issue>8</issue><spage>639</spage><epage>646</epage><pages>639-646</pages><issn>1320-5358</issn><eissn>1440-1797</eissn><abstract>Depression is the most common psychiatric illness in patients with end‐stage renal disease (ESRD). The reported prevalence of depression in dialysis population varied from 22.8% (interview‐based diagnosis) to 39.3% (self‐ or clinician‐administered rating scales). Such differences were attributed to the overlapping symptoms of uraemia and depression. Systemic review and meta‐analysis of observational studies showed that depression was a significant predictor of mortality in dialysis population. The optimal screening tool for depression in dialysis patients remains uncertain. The Beck Depression Inventory (BDI), Patient Health Questionnaire (PHQ) and Center for Epidemiologic Studies Depression Scale (CESD) have been validated for screening purposes. Patients who scored ≥14 using BDI should be referred to a psychiatrist for early evaluation. Structured Clinical Interview for DSM disorders (SCID) remains the gold standard for diagnosis. Non‐pharmacological treatment options include cognitive behavioural therapy and exercise training programs. Although frequent haemodialysis may have beneficial effects on patients' physical and mental well‐being, it cannot and should not be viewed as a treatment of depression. Selective serotonin reuptake inhibitors (SSRIs) are generally effective and safe in ESRD patients, but most studies were small, non‐randomized and uncontrolled. The European Renal Best Practice (ERBP) guideline suggests a trial of SSRI for 8 to 12 weeks in dialysis patients who have moderate–major depression. The treatment effect should be re‐evaluated after 12 weeks to avoid prolonging ineffective medication. This review will discuss the current understanding in the diagnosis and management of depression in dialysis patients. Summary at a Glance This review examines some current features of the diagnosis and management of depression in dialysis patients. The overlapping symptoms of kidney failure managed with dialysis and depression and their interpretation are highlighted. The evidence and rationale for treatment are discussed.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>26860073</pmid><doi>10.1111/nep.12742</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1320-5358
ispartof Nephrology (Carlton, Vic.), 2016-08, Vol.21 (8), p.639-646
issn 1320-5358
1440-1797
language eng
recordid cdi_proquest_miscellaneous_1808639964
source Wiley-Blackwell Read & Publish Collection
subjects Antidepressive Agents - therapeutic use
Cognitive ability
Cognitive Therapy
depression
Depression - diagnosis
Depression - epidemiology
Depression - psychology
Depression - therapy
Diagnosis
Dialysis
Epidemiology
Hemodialysis
Humans
Kidney Failure, Chronic - diagnosis
Kidney Failure, Chronic - epidemiology
Kidney Failure, Chronic - psychology
Kidney Failure, Chronic - therapy
Medicare
Mental depression
Patients
Physical training
Predictive Value of Tests
Psychiatric Status Rating Scales
Renal Dialysis - adverse effects
Risk Factors
Serotonin uptake inhibitors
Severity of Illness Index
Surveys and Questionnaires
Treatment Outcome
title Depression in dialysis patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A42%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Depression%20in%20dialysis%20patients&rft.jtitle=Nephrology%20(Carlton,%20Vic.)&rft.au=Ma,%20Terry%20King%E2%80%90Wing&rft.date=2016-08&rft.volume=21&rft.issue=8&rft.spage=639&rft.epage=646&rft.pages=639-646&rft.issn=1320-5358&rft.eissn=1440-1797&rft_id=info:doi/10.1111/nep.12742&rft_dat=%3Cproquest_cross%3E1806076418%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5252-351e002c6c56b908cf1809cde5888ec85feb129bb148c455de98376e31b109cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2049769681&rft_id=info:pmid/26860073&rfr_iscdi=true